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A B S T R A C T
Background
This is an updated version of the Cochrane Review previously published in Issue 3, 2015.
The incidence of seizures following supratentorial craniotomy for non-traumatic pathology has been estimated to be between 15%
to 20%; however, the risk of experiencing a seizure appears to vary from 3% to 92% over a five-year period. Postoperative seizures
can precipitate the development of epilepsy; seizures are most likely to occur within the first month of cranial surgery. The use of
antiepileptic drugs (AEDs) administered pre- or postoperatively to prevent seizures following cranial surgery has been investigated in a
number of randomised controlled trials (RCTs).
Objectives
To determine the efficacy and safety of AEDs when used prophylactically in people undergoing craniotomy and to examine which
AEDs are most effective.
Search methods
For the latest update we searched the following databases on 26 June 2017: Cochrane Epilepsy Group Specialized Register, the
CENTRAL, MEDLINE, ClinicalTrials.gov, and theWHO International Clinical Trials Registry Platform (ICTRP). We did not apply
any language restrictions.
Selection criteria
We included RCTs of people with no history of epilepsy who were undergoing craniotomy for either therapeutic or diagnostic reasons.
We included trials with adequate randomisation methods and concealment; these could either be blinded or unblinded parallel trials.
We did not stipulate a minimum treatment period, and we included trials using active drugs or placebo as a control group.
Data collection and analysis
Three review authors (JW, JG, YD) independently selected trials for inclusion and performed data extraction and risk of bias assessments.
We resolved any disagreements through discussion. Outcomes investigated included the number of participants experiencing seizures
(early (occurring within first week following craniotomy), and late (occurring after first week following craniotomy)), the number of
deaths and the number of people experiencing disability and adverse effects. Due to the heterogeneous nature of the trials, we did not
combine data from the included trials in a meta-analysis; we presented the findings of the review in narrative format. Visual comparisons
of outcomes are presented in forest plots.
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Main results
We included 10 RCTs (N = 1815), which were published between 1983 and 2015. Three trials compared a single AED (phenytoin)
with placebo or no treatment. One three-armed trial compared two AEDs (phenytoin, carbamazepine) with no treatment. A second
three-armed trial compared phenytoin, phenobarbital with no treatment. Of these five trials comparing AEDs with placebo or no
treatment, two trials reported a statistically significant advantage for AED treatment compared to controls for early seizure occurrence;
all other comparisons showed no clear or statistically significant differences between AEDs and control treatment. None of the trials that
were head-to-head comparisons of AEDs (phenytoin versus sodium valproate, phenytoin versus phenobarbital, levetiracetam versus
phenytoin, zonisamide versus phenobarbital) reported any statistically significant differences between treatments for either early or late
seizure occurrence.
Incidences of death were reported in only five trials. One trial reported statistically significantly fewer deaths in the carbamazepine
and no-treatment groups compared with the phenytoin group after 24 months of treatment, but not after six months of treatment.
Incidences of adverse effects of treatment were poorly reported; however, three trials did show that significantly more adverse events
occurred on phenytoin compared to valproate, placebo, or no treatment. No trials reported any results relating to functional outcomes
such as disability.
We considered the evidence to be of low quality for all reported outcomes due to methodological issues and variability of comparisons
made in the trials.
Authors’ conclusions
There is limited, low-quality evidence to suggest that AED treatment administered prophylactically is either effective or not effective
in the prevention of postcraniotomy (early or late) seizures. The current evidence base is limited due to the different methodologies
employed in the trials and inconsistencies in the reporting of outcomes including deaths and adverse events. Further evidence from
good-quality, contemporary trials is required in order to assess the clinical effectiveness of prophylactic AED treatment compared to
placebo or no treatment, or other AEDs in preventing postcraniotomy seizures in this select group of patients.
P L A I N L A N G U A G E S U M M A R Y
The use of antiepileptic drugs to prevent seizures following brain surgery
Review question
This Cochrane Review examines the evidence for the effectiveness and safety of antiepileptic drugs (AEDs) when they are given to
people who do not have epilepsy to prevent them experiencing seizures after craniotomy surgery (a type of brain surgery commonly
used to remove brain tumours). We also planned to assess whether any particular AED is more effective in preventing seizures after
craniotomy surgery.
Background
People who undergo a type of brain surgery known as craniotomy may be at increased risk of experiencing seizures after craniotomy
surgery. AEDs have been used in trials to prevent seizures occurring after surgery in people with no previous history of epilepsy. A small
number of trials have compared different AED treatments against each other, while others have compared AEDs to a placebo (a pill
that contains no medicine) or no-treatment group.
Study characteristics
The evidence is current to June 2017. Ten trials met our inclusion criteria, and included 1815 people. Three trials compared phenytoin
(an AED) with a placebo or no treatment. One trial compared the AEDs phenytoin or carbamazepine with no treatment. One trial
compared the AEDs phenytoin or phenobarbital with no treatment. Five other trials were head-to-head trials (where one drug is
directly compared against another drug) of AEDs (phenytoin versus valproate; zonisamide versus phenobarbital and levetiracetam
versus phenytoin).
Key findings
We did not find any consistent evidence to suggest that preventative AED treatments are effective in reducing the number of seizures
that occurred postsurgery, deaths or adverse effects.
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Quality of the evidence
Taking all the trials together, we considered that the quality of the evidence was low due to potential problems with the designs of the
trials. Also the differences in the designs of the trials relating to the treatments examined and the results reported meant that it was
difficult to compare results across trials. Further good-quality studies are needed to validate the findings mentioned above.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Antiepileptic drugs as prophylaxis for postcraniotomy seizures
Patient or population: people with postcraniotomy seizures
Settings: hospital sett ing
Intervention: ant iepilept ic drugs
Control: another ant iepilept ic drug, placebo or no treatment
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Antiepileptic drugs
Early seizures
(number of people with
seizures)
Follow-up: up to 1 week
See comment See comment Not est imable 1539
(9 trials)
⊕⊕©©
lowa,b
7 trials found no signif i-
cant dif f erences across
comparisons examined:
phenytoin vs no treat-
ment, phenobarbital or
phenytoin vs no treat-
ment, phenytoin vs val-
proate, levet iracetam vs
phenytoin and zon-
isamide vs phenobarbi-
tal
2 trials found a signif i-
cant ly lower number of
seizures following use
of phenytoin vs no treat-
ment.c
Late seizures
(number of people with
seizures)
Follow-up: 1 week up to
4 years (median)
See comment See comment Not est imable 798
(5 trials)
⊕⊕©©
lowa,b
All t rials found no signif -
icant dif f erences across
comparisons examined;
phenytoin vs placebo
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or no treatment, phe-
nobarbital or phenytoin
vs no treatment, pheny-
toin vs valproate, zon-
isamide vs phenobarbi-
tal
Death
(number of deaths)
Follow-up: up to 4 years
(median)
See comment See comment Not est imable 1016
(5 trials)
⊕⊕©©
lowa,b
4 trials found no sig-
nif icant dif f erences over
comparisons: phenytoin
vs valproate, zon-
isamide vs phenobar-
bital; levet iracetam vs
phenytoin and phenytoin
vs placebo
1 trial found signif i-
cant ly fewer deaths in
the carbamazepine and
the no-treatment group
at 24 months com-
pared to phenytoin.d
This trial showed no sig-
nif icant dif f erence be-
tween the intervent ions
at 6 months
Functional outcome
(number of people with
disabilit ies)
Follow-up: NA
See comment See comment Not est imable NA NA No included studies re-
ported a funct ional out-
come.
Adverse effects
(number of people with
adverse events)
Follow-up: up to 12
months
See comment See comment Not est imable 1165
(8 trials)Text in Ef fects
of intervent ions gives
some dif ferent numbers
of part icipants. I have
amended to what I think
it should be and used
⊕⊕©©
lowa,b
Most trials found low
numbers of adverse ef -
fects, and f ive trials
found that no signif icant
dif f erences across com-
parisons were reported
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t racked changes and
highlight ing to make the
changes visible. Please
check and amend as
necessary
Two trials found that sig-
nif icant ly more adverse
events were reported on
phenytoin compared to
placebo or no treatment
e and one trial found
that signif icant ly more
adverse events were
reported on phenytoin
compared valproate.f
* The basis for the assumed risk (e.g. the median control group risk across trials) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is based
on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; NA: not applicable
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate; the true ef fect is likely to be close to the est imate of ef fect, but there is a possibility that it is substant ially
dif f erent.
Low quality: we are moderately conf ident in the ef fect est imate; the true ef fect is likely to be close to the est imate of ef fect, but there is a possibility that it is substant ially
dif f erent.
Very low quality: we have very lit t le conf idence in the ef fect est imate; the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded once due to risk of bias: methodological biases ident if ied in trials (no allocat ion concealment, one study
unblinded, unclear methods of dealing with missing data).
bDowngraded once due to inconsistency: all t rials dif f ered in comparisons made.
cLee 1989 and North 1983 found number of seizures was signif icant ly lower in the phenytoin group compared to placebo
group.
dFoy 1992 found large dif ferences in the number of deaths between treatment groups. Stat ist ical signif icance level unreported.
eNorth 1983 and Wu 2013 reported signif icant ly higher overall adverse events in the phenytoin group compared to placebo or
no treatment respect ively.
f Zhang 2000 reported signif icant ly higher overall adverse events in the phenytoin group compared to valproate group.
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B A C K G R O U N D
This is an updated version of the Cochrane Review previously
published in Issue 3, 2015.
Description of the condition
The incidence of epilepsy following supratentorial craniotomy for
non-traumatic pathology has been estimated to be 15% to 20% (
Foy 1981); however, due to the nature of the underlying disease for
which surgery is undertaken, the risk of postcraniotomy seizures
appears to vary from 3% to 92% over a five-year period. It is
likely that such seizuresmay cause epilepsy in previously unaffected
people. The probability of de novo seizures occurring in people
who have no history of epilepsy decreases over time after surgery.
The highest incidence of postoperative epilepsy (two-thirds of the
seizures) occurs within the first month after cranial surgery (North
1983), and 75% of those who develop epilepsy do so within one
year of surgery. Few people (approximately 8%) have their first
seizure more than two years after surgery. The risk of seizures for
particular groups of people is higher for some groups than others;
for example, people who suffer from an abscess continue to run
a high risk of developing epilepsy (92%) after five years, whilst
for those with an arteriovenous malformation who have had a
spontaneous intracerebral haematoma, the overall risk does not
fall below 10% between year two and year five after surgery (Shaw
1991).
Description of the intervention
Due to the risk of postoperative seizures, the prophylactic use of
antiepileptic drugs (AEDs) has been advocated for people under-
going cranial surgery. However, it is also argued that AEDs should
not be used prophylactically, but should only be administered fol-
lowing at least one seizure (Temkin 2002). Other investigators
maintain that early postoperative seizures do not justify the diag-
nosis of epilepsy and only late seizures are considered to be true
epilepsy (Manaka 2003).
How the intervention might work
Uncontrolled retrospective trials support the use of AED treat-
ment in people with a predisposition towards developing postop-
erative seizures (Matthew 1980), and data from pathological trials
suggest that certain AEDs could have a neuro-protective action on
damaged cerebral cortex (Calabresi 2003).
Why it is important to do this review
To informdecisionmaking regarding the prophylactic use of AEDs
for people undergoing craniotomy, reliable high-quality evidence
is required. Benefits and harms and any trade-offs between these
need to be examined carefully. Potential benefits include reduced
short-term seizure recurrence, reduced long-term epilepsy rates,
and better surgical outcome and quality of life. Harms include
adverse effects and poorer surgical outcome. This Cochrane Re-
view will provide a summary of the currently available evidence
from randomised controlled trials (RCTs) regarding the prophy-
lactic use of AEDs for people undergoing craniotomy by examin-
ing the following outcomes: occurrence of early and late seizures,
occurrence of death, functional disability and occurrence of ad-
verse events.
O B J E C T I V E S
To determine the efficacy and safety of AEDs when used prophy-
lactically in people undergoing craniotomy and to examine which
AEDs are most effective.
M E T H O D S
Criteria for considering studies for this review
Types of studies
1. RCTs
2. Double-blinded, single-blinded or unblinded trials
3. Placebo-controlled, active drug-control group or no-
treatment control group
Types of participants
People of any age and either gender undergoing a supratentorial
or infratentorial craniotomy for either therapeutic or diagnostic
reasons for all pathologies, who have had no history of seizures or
prior exposure to AEDs.We excluded people with traumatic brain
injuries from this review.
Types of interventions
1. The active treatment groups received treatment with any
AED administered prior to or immediately postcraniotomy
2. The control groups received matched placebo, different
AEDs or no treatment
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Types of outcome measures
Primary outcomes
1. Early seizures
The proportion of people experiencing seizures occurring within
the first week following craniotomy.
2. Late seizures
The proportion of people experiencing seizures occurring after
the first week following craniotomy, including follow-up period
of one, two and five years postoperatively.
Secondary outcomes
1. Death
The proportion of deaths that occurred within the treatment pe-
riod or during follow-up.
2. Functional outcome
The proportion of people who experienced disability (partially or
fully dependent on others in normal activities of daily living).
3. Adverse effects
The proportion of people who experienced any of the following
adverse events.
1. Skin irritation
2. Dizziness
3. Fatigue
4. Nausea
5. Headache
In addition, we decided to look at the proportion of people who
experienced the five most common adverse effects mentioned in
the included trials if these differed from the list above.
Search methods for identification of studies
Electronic searches
We ran searches for the original review in January 2012 and sub-
sequent searches in September 2012, August 2014, August 2016,
and June 2017. For the latest update we searched:
1. The Cochrane Epilepsy Group Specialized Register (26
June 2017) using the search strategy outlined in Appendix 1.
2. The Cochrane Central Register of Controlled Trials
(CENTRAL; 2017 issue 6) via the Cochrane Register of Studies
Online (CRSO), using the search strategy outlined in Appendix
2.
3. MEDLINE (Ovid, 1946 to 26 June 2017) using the search
strategy outlined in Appendix 3.
4. ClinicalTrials.gov (26 June 2017) using the search strategy
outlined in Appendix 4.
5. WHO International Clinical Trials Registry Platform
(ICTRP, 26 June 2017) using the search strategy outlined in
Appendix 5.
We did not impose any language restrictions.
Searching other resources
We reviewed the reference lists of retrieved trials to check for ad-
ditional reports of relevant studies.
Data collection and analysis
Selection of studies
Three review authors (JW, JG and YD) independently assessed
articles for inclusion. We resolved any disagreements through dis-
cussion, and failing this, we sought the opinion of a fourth re-
view author (AM). The same review authors independently carried
out data extraction and assessed risk of bias. Again, we resolved
any disagreements through discussion. Failing this, we sought the
opinion of the fourth review author (AM).
Data extraction and management
We extracted the following information for each trial using a data
extraction sheet.
Methodology/trial design
1. Method of randomisation and concealment
2. Method of blinding
3. Number of people excluded from analyses
4. Duration of baseline, treatment and follow-up periods
5. Type of AED and dose tested
6. Time of treatment commencement
Participant demographics
1. Total number of people randomised to each group
2. Age/gender
3. Pathological group
4. Type of surgery
5. Site of lesion
6. Number of people with previous acute symptomatic seizures
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Results
1. Sample size
2. Summary data for each intervention
For all trials we attempted to confirm the above information with
trial authors or researchers, and sponsors.
Assessment of risk of bias in included studies
Three review authors (JW, JG and YD) independently assessed the
risk of bias for each trial using the Cochrane ’Risk of bias’ tool,
as described in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). We resolved any disagreements by
discussion. We rated the included trials as low, high or unclear on
six domains applicable to RCTs: randomisation method, alloca-
tion concealment, blinding methods, incomplete outcome data,
selective outcome reporting and other sources of bias (Assessment
of risk of bias in included studies).
Measures of treatment effect
We have presented treatment effects as they were reported in the
original reports. In this latest update, where data for each trial
are entered into Data and analyses tables to allow for visual com-
parisons of results across trials, we have presented results for all
dichotomous outcomes as risk ratios (RR) and 95% confidence
intervals (CI).
Unit of analysis issues
The unit of allocation and analysis had to be the individual for all
included trials, therefore cluster-RCTs were not an eligible design.
Due to the acute nature of postcraniotomy seizures, cross-over
designs were also not a suitable design.
For included trials with more than two treatment arms (e.g.
AED1 versus AED2 versus placebo), we considered pairs of in-
terventions in separate head-to-head comparisons (see Effects of
interventions).
Dealing with missing data
Werecorded attrition rates reported in each trial and if appropriate,
attempted to contact original trial authors where the extent of
missing data was unclear. In order to allow an intention-to-treat
analysiswithin this review,we collected data by allocated treatment
groups, irrespective of compliance, later exclusion (regardless of
cause) or loss to follow-up.
Assessment of heterogeneity
We assessed clinical heterogeneity by examining the differences
in trial characteristics in order to inform decisions regarding the
combination of trial data (Higgins 2002). Due to high levels of
clinical heterogeneity, we did not synthesis any outcome data, If
we had performed meta-analysis, we would have estimated het-
erogeneity statistically using a Chi2 test for heterogeneity (with a
conservative judgement of P value < 0.1 suggesting heterogeneity)
and the I2 statistic, interpreted as follows (Deeks 2011):
• might not be important (I2 values 0% to 40%);
• may represent moderate heterogeneity (I2 values 30% to
60%);
• may represent substantial heterogeneity (I2 values 50% to
90%); and
• considerable heterogeneity (I2 values 75% to 100%).
Assessment of reporting biases
We examined reporting biases, such as publication bias, by iden-
tifying specific aspects of each trial (e.g. sponsors of the research,
research teams involved).
Data synthesis
It was not possible to synthesise outcome data as we considered
meta-analysis to be inappropriate given the differences across trials
in AED treatment, trial intervention characteristics and control
groups (see Table 1).
We have presented study-specific results for the following com-
parisons.
1. Treatment group versus control group on early seizures
2. Treatment group versus control group on late seizures
3. Treatment group versus control group on number of deaths
4. Treatment group versus control group on functional
outcome
5. Treatment group versus control group on adverse effects
(for each adverse effect see Types of outcome measures)
We stratified each comparison by type of drug and control group
(i.e. placebo, other AEDor no treatment) and presented the study-
specific results for comparison without synthesising in Data and
analyses.
Subgroup analysis and investigation of heterogeneity
We did not plan any subgroup analyses a priori. The main sources
of heterogeneity anticipated were the different trial interventions
and control groups (consideredwithin separate comparisons in this
review) and different time points of measures (considered within
different outcomes of this review).
Sensitivity analysis
We considered a sensitivity analysis of the primary outcomes of the
review (where possible) based on themethodological quality of the
studies, restrictingmeta-analysis to only studies with a globally low
risk of bias. However, given the minimal amount of data available
for each comparison and the fact that we considered only two
studies to have a low risk of bias due to lack of blinding, we did
not deem this sensitivity analysis appropriate.
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Summary of findings and quality of the evidence
(GRADE)
Due to the variability of interventions and control groups within
the included studies in this review, we have presented a single
’Summary of findings’ table for all comparisons considered within
this review (Schünemann 2011; Summary of findings for themain
comparison).
We have included all primary and secondary outcomes in the
’Summary of findings’ table. We determined the quality of the
evidence using the GRADE approach (GRADE Working Group
2004), and downgraded evidence in the presence of a high risk of
bias in at least one study, indirectness of the evidence, unexplained
heterogeneity or inconsistency, imprecision of results and high
probability of publication bias. We downgraded evidence by one
level if we considered the limitation to be serious and by two levels
if very serious.
R E S U L T S
Description of studies
Results of the search
Our searches identified 157 records from the databases outlined in
the Electronic searches section.We identified 10 additional records
through the reference lists of the included trials. Eighty-seven
records remained after we removed duplicates, and we screened
all for inclusion in the review. We excluded 60 records at this
point, leaving 27 full-text articles to be assessed for eligibility. Fol-
lowing this, we excluded 15 full-text articles (see Figure 1 and
Characteristics of excluded studies for reasons for exclusion). We
included 10 trials from 12 reports in a narrative synthesis.
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Figure 1. Study flow diagram
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Included studies
We identified 10 parallel RCTs (Beenen 1999; Foy 1992;
Franceschetti 1990; Fuller 2013; Iuchi 2015; Lee 1989;Nakamura
1999; North 1983; Wu 2013; Zhang 2000), examining the ef-
fectiveness of AEDs on postcraniotomy seizures in 1815 people.
We have presented treatment protocols of the 10 included trials
in Table 1.
The treatment periods varied across trials from three days to
24 months; in one trial the treatment period was unclear
(Franceschetti 1990). People were excluded from six of the trials if
they were taking AEDs already or if they had a history of epilepsy
(Beenen1999; Foy 1992; Lee 1989;Nakamura 1999;North1983;
Zhang 2000). One trial (Franceschetti 1990), included both peo-
ple who had pre-operative seizures (Group A) and those who did
not (Group B). They analysed Group A and Group B separately
compared to controls. We only extracted data pertaining to Group
B to be included within this Cochrane Review, as Group A did
not meet our inclusion criteria. One trial (Iuchi 2015), included
people who had pre-operative seizures, but the trial authors pro-
vided the results of a subgroup analysis for participants with no
pre-operative seizures.
Beenen 1999 was a single-centre trial with a treatment period of
12 months. People aged between 18 and 80 years who were un-
dergoing supratentorial craniotomy were eligible for inclusion in
the trial. 100 patients were randomised: 50 to phenytoin 100 mg
and 50 to valproate 500 mg treatment. They administered both
treatments intravenously immediately postoperatively in a recov-
ery room. Outcomes reported included early and late seizures,
death and adverse effects. They did not report any data for func-
tional outcome.
Foy 1992 was a single-centre, head-to-head, three-armed trial with
a treatment period of either six or 24 months, and follow-up of
three years to a maximum of eight years. People aged over 16 years
undergoing supratentorial craniotomy were eligible for inclusion
in the trial. The trial authors randomised 276 patients: 55 to
phenytoin for a six-month treatment period, 56 to phenytoin for a
24-month treatment period, 50 to carbamazepine for a six-month
treatment period, 56 to carbamazepine for a 24-month treatment
period and 59 to no treatment. Phenytoin (15 mg/kg) was ad-
ministered 24 hours pre-operation and increased to 100 mg eight-
hourly thereafter. Administration of carbamazepine (200 mg) was
every six hours for the 24 hours immediately pre-operatively and
every eight hours thereafter. Outcomes reported included number
of participants with seizures and death. The trial did not differ-
entiate between early and late seizures, and no data were reported
for functional outcome or adverse effects. All data were reported
at six months into the treatment.
Franceschetti 1990 was a single-centre, head-to-head, three-armed
trial that included a no-treatment group. The duration of treat-
ment is unclear. The trial randomised people undergoing surgery
for supratentorial neoplasms; those with a history of seizures
formed Group A and those with no history of seizures formed
Group B. Group A participants were not eligible for inclusion in
this review but there were 63 people randomised to Group B: 25
to phenobarbital, 16 to phenytoin and 22 to no treatment. The
phenobarbital (4 mg/kg) was intravenously administered daily for
five days and then decreased to 2 mg/kg daily via oral administra-
tion. Phenytoin (10 mg/kg) was intravenously administered daily
for five days and then decreased to 5 mg/kg daily via oral adminis-
tration. Outcomes reported included early and late seizures. Min-
imal data on adverse effects were presented.
Fuller 2013 was a single-centre, head-to-head, two-arm trial with
a treatment period of 90 days. People aged 18 years and over
undergoing craniotomy were eligible for inclusion in the trial.
The trial randomised 81 people, 39 to levetiracetam and 42 to
phenytoin. They administered levetiracetam (250 mg to 500 mg)
twice daily, either intravenously or orally (one pre-operative dose
was required) and phenytoin (1000 mg loading dose followed by
300 mg) daily. Outcomes measured included discontinuation of
treatment due to side effects, and clinically undesirable event and
seizure occurrence. Outcomes were reported at three days and at
90 days.
Iuchi 2015 was a single-centre, head-to-head, two-arm trial with a
treatment period and follow-up of seven days. People aged 16 years
and over with supratentorial tumours undergoing craniotomy
were eligible for inclusion in the trial. The trial randomised a total
of 147 people, including 110 people with no history of seizures.
Of these, 52 people received levetiracetam and 58 people received
phenytoin; levetiracetam (500 mg) was administered twice daily
after anaesthesia induction either by suppository or orally, and
phenytoin (15 to 18 mg/kg intravenously after induction of anaes-
thesia and continued at 5 mg/kg to 7.5 mg/kg daily intravenously
or 250 mg orally). Outcomes measured included seizure occur-
rence and adverse events. Outcome data were reported at seven
days. No data on functional outcomes were collected.
Lee 1989 was a placebo-controlled trial with a treatment period
of three days. The number of participating treatment centres is
unclear. Adults receiving intracranial, supratentorial surgery were
eligible to take part in the trial. The trial authors selected and ran-
domised 400 patients for participation, however, 26 early deaths
occurred, leaving 189 people randomised to phenytoin and 185
people to placebo. Phenytoin (15 mg/kg) was administered 15
to 20 minutes prior to wound closure followed by intravenous
phenytoin (5 mg/kg to 6 mg/kg) three times daily for the first
three postoperative days. Outcomes measured included number
of seizures occurring within the three days of the trial. Data for
late seizures, death, functional outcome and adverse effects were
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not recorded.
Nakamura 1999was amulti-centre, head-to-head trial with a treat-
ment phase of one year and a follow-up after two years postmedi-
cation. Adults undergoing craniotomy for cerebral tumours, cere-
brovascular disease and head trauma were selected for eligibility.
The trial randomised 278 people: 129 to zonisamide (100 mg
twice daily) and 126 to phenobarbital (40 mg twice daily). How-
ever, 23 participants (12 randomised to zonisamide and 11 ran-
domised to phenobarbital) were excluded from the final analysis
due to protocol violations. Both drugs were administered orally,
at least one week before surgery and then increased (zonisamide to
100 mg three or four times daily and phenobarbital to 40 mg three
or four times daily) for one year followed by a tapering period of
six months (three months at 100 mg (zonisamide) or 40 mg (phe-
nobarbital) twice daily then three months at 100 mg (zonisamide)
or 40 mg (phenobarbital) once daily). Outcomes reported were
seizure frequency, death (during follow-up period only) and ad-
verse effects. No data were collected on functional outcome.
North 1983 was a single-centre, placebo-controlled trial with a
treatment period of 12 months. People undergoing supratentorial
operation (either burr hole, craniectomy or osteoplastic flap proce-
dures) were eligible for inclusion in the trial. The trial authors ran-
domised 281 people: 140 to phenytoin and 141 to placebo. Pheny-
toin (250 mg twice daily) was administered in a recovery room
intravenously, and then continued with oral medication (100 mg
three times daily) for one year. Outcomes reported were early and
late seizures, death and adverse effects. No data were collected on
functional outcomes.
Wu 2013 was a single-centre, no-treatment controlled trial with
a treatment period of seven days. People with supratentorial tu-
mours were eligible for inclusion in the trial. The trial authors ran-
domised 123 people, 62 to phenytoin and 61 to a no-treatment
control group . Following a pre-operative loading dose of 15 mg/
kg, phenytoin (100 mg) was administered every eight hours to the
treatment group. Outcomes reported were seizure occurrence and
adverse reactions. No data relevant to functional outcomes were
reported.
Zhang 2000 was a single-centre, head-to-head trial with a treat-
ment period of one month. The trial randomised 152 people un-
dergoing craniotomy for differing pathologies, 72 to phenytoin
and 80 to valproate. Treatment with phenytoin (10 mg/kg) and
valproate (30 mg/kg) was given orally three times daily for seven
days before surgery. Outcome measures included seizure occur-
rence and adverse effects of treatment. No data relevant to func-
tional outcomes were reported.
Excluded studies
Overall we excluded 15 full-text articles for the following reasons:
seven were not RCTs (Baker 1995; Boarini 1985; De Santis 1996;
Grobelny 2009; Hayashi 1999; Murri 1992; Notani 1984), two
were review articles (Manaka 2003; Shaw 1991), and six studies
had participants that did not meet our inclusion criteria (De
Santis 2002; Levati 1996; Lim 2009; Temkin 1990; Temkin 1999;
Tsolaki 1987).
Risk of bias in included studies
SeeCharacteristics of included studies tables and Figure 2 for ’Risk
of bias’ judgements.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included trials
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Allocation
For sequence generation, we rated two trials at low risk of bias
(Beenen 1999; Foy 1992), and eight trials at unclear risk of bias
(Franceschetti 1990; Fuller 2013; Iuchi 2015 Lee 1989;Nakamura
1999; North 1983; Wu 2013; Zhang 2000). We did not rate any
trials at high risk of bias.
For allocation concealment, we rated one study at low risk of bias
(Beenen 1999), and nine trials (Foy 1992; Franceschetti 1990;
Fuller 2013; Iuchi 2015 Lee 1989; Nakamura 1999; North 1983;
Wu 2013; Zhang 2000), at unclear risk of bias due to the lack of
detail of these methods.
Blinding
We rated four trials at low risk of bias due to themethods of blind-
ing employed (Beenen 1999; Lee 1989; Nakamura 1999; North
1983). We rated three trials at unclear risk of bias (Franceschetti
1990; Fuller 2013; Zhang 2000), and three trials at high risk of
bias, as only the outcome assessor appeared to be blinded in two
trials (Foy 1992; Wu 2013), and the other trial was unblinded
(Iuchi 2015).
Incomplete outcome data
We rated four trials at low risk of bias due to having no missing
data (Beenen 1999; Iuchi 2015; North 1983;Wu 2013).We rated
six trials at unclear risk of bias due to lack of detail regarding the
analysis (Foy 1992; Franceschetti 1990; Fuller 2013; Lee 1989;
Nakamura 1999; Zhang 2000). We did not rate any trials at high
risk of bias.
Selective reporting
We rated all of the included trials at unclear risk of bias due to the
lack of protocols available for comparison. We requested protocols
from the trial authors if contact details were available, however we
did not receive any responses.
Other potential sources of bias
We rated seven trials at low risk of bias as we did not identify any
other bias (Beenen 1999; Franceschetti 1990; Fuller 2013; Iuchi
2015; Lee 1989; Nakamura 1999; North 1983). We rated three
trials at unclear risk of bias (Foy 1992; Wu 2013; Zhang 2000).
Effects of interventions
See: Summary of findings for the main comparison
Antiepileptic drugs as prophylaxis for postcraniotomy seizures
Due to the variety of head-to-head drug comparisons within the
included trials (see Table 1 for a comparison of treatment proto-
cols), we have presented the effects of the interventions by out-
come measure as opposed to comparisons under trial.
Seizures
See Table 2 for individual trial results, and see Analysis 1.1 for
comparative results for all seizures, Analysis 1.2 for early seizures
and Analysis 1.3 for late seizures.
Any seizures
All 10 trials, with a total of 1815 participants, reported results
for the proportion of people experiencing any seizures. Foy 1992
reported only occurrence of seizures (without the time frame);
they found no statistically significant differences between any of
the treatment groups. All other trials reported whether the seizures
were early (i.e. within one week) or late (i.e. after one week).
Early seizures
Nine trials (N =1539) reported the number of people experiencing
early seizures.
Phenytoin versus placebo or no treatment
Lee 1989 reported two seizures in 189 participants (1%) in the
phenytoin group compared to nine seizures in 185 participants
(5%) in the placebo group.North 1983 reported four early seizures
in 140 participants (3%) in the phenytoin group compared to
14 seizures in 141 participants (10%) in the placebo group. Wu
2013 reported two early seizures in 62 participants (3%) in the
phenytoin group compared to five in 61 participants (8%) in the
no-treatment group. Lee 1989 and North 1983 reported a statisti-
cally significant difference in favour of treatment with phenytoin.
Within the Lee 1989 published paper, the trial authors reported no
statistically significant difference between phenytoin and placebo,
however, they applied a Yates correction to their analysis methods,
which may have led to the difference in the results between the
published paper and this review.
Phenobarbital or phenytoin versus no treatment
Franceschetti 1990 reported three early seizures occurring in 41
participants (17%) in the phenobarbital and phenytoin groups
and four in 22 participants (18%) in the no-treatment group.
The difference in early seizures between the two groups was not
statistically significant.
Phenytoin versus valproate
Beenen 1999 reported four early seizures in 50 participants (8%)
in the phenytoin group compared to two in 50 participants (14%)
in the valproate group. Zhang 2000 reported six early seizures in
72 participants (8%) in the phenytoin group compared to nine in
80 participants (11%) in the valproate group. Neither trial found
a statistically significant difference in early seizures between the
two treatment groups.
Levetiracetam versus phenytoin
Fuller 2013 reported no early seizures in 39 participants in the
levetiracetam group and six in 42 participants (14%) in the pheny-
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toin group. Iuchi 2015 reported one early seizure in 53 partici-
pants (2%) in the levetiracetam group and eight in 58 participants
(14%) in the phenytoin group.Within this Cochrane Review, nei-
ther result was statistically significant. However, within both of
the published reports of the trials, the trial authors noted a statis-
tically significant advantage of treatment with levetiracetam. We
believe that the differences between the published reports and this
review are due to different measures being used; this review uses
risk ratios, whilst Fuller 2013 used log-rank methods and Iuchi
2015 reported odds ratios.
Zonisamide versus phenobarbital
Nakamura 1999 reported six early seizures in 129 participants
(5%) in the zonisamide group compared to three in 126 partic-
ipants (2%) in the phenobarbital group. The difference in early
seizures between the two groups was not statistically significant.
Summary
Overall, the quality of the evidence for this outcome was low due
to unclear risk of bias and variability of treatment protocols in the
included trials. Two trials reported a significant difference between
AED treatment and no treatment or placebo for early seizure oc-
currence (Lee 1989; North 1983). No significant differences be-
tween the treatments were reported in the other trials (Analysis
1.2).
Late seizures
Five trials, with a total of 798 participants, reported the number
of people experiencing late seizures.
Phenytoin versus placebo or no treatment
North 1983 reported 14 late seizures in 140 participants (10%) in
the phenytoin group compared to 12 late seizures in 141 partici-
pants (9%) in the control group at 12 months. Wu 2013 reported
13 late seizures in 62 participants (21%) in the phenytoin group
compared to six late seizures in 61 participants (10%) in the con-
trol group beyond 30 days. The difference in late seizures between
the two groups was not statistically significant.
Phenobarbital or phenytoin versus no treatment
The Franceschetti 1990 trial only followed up 39 participants,
and reported two late seizures in 25 participants (13%) in the
phenobarbital group, one late seizure in 10 participants (10%)
in the phenytoin group and three late seizures in 14 participants
(21%) in the no-treatment group. The timing of the follow-up is
unclear. The difference in late seizures between the treatment and
no-treatment groups was not statistically significant.
Phenytoin versus valproate
Beenen 1999 reported three late seizures in 50 participants (6%)
in the phenytoin group compared with five late seizures in 50
participants (10%) in the valproate group at up to 12 months.
Zonisamide versus phenobarbital
Nakamura 1999 reported seven late seizures in 129 participants
(5%) in the zonisamide group and eight late seizures in 126 par-
ticipants (6%) in the phenobarbital group at 12 months. The dif-
ference in late seizures between the two groups was not statistically
significant.
Summary
Overall, the quality of the evidence for this outcome was low
due to risk of bias and variability of treatment protocols in the
included trials. None of the trials that reported data for late seizures
found any statistically significant differences between treatment
and controls (Analysis 1.3).
Deaths
Five trials, with a total of 1016 participants, reported the number
of deaths that occurred during the trials. See Table 3 for individual
trial results and see Analysis 1.4 for comparative results for deaths.
Five trials did not present data for the outcome of death
(Franceschetti 1990; Iuchi 2015; Lee 1989; Wu 2013; Zhang
2000).
Phenytoin versus placebo or no treatment
North 1983 reported 20 deaths in 140 participants (14%) in the
phenytoin group and 24 deaths in 141 participants (17%) in the
placebo group.
Carbamazepine versus phenytoin versus no treatment
Foy 1992 reported nine deaths in 50 participants (18%) in the
carbamazepine group, 15 deaths in 55 participants (27%) in the
phenytoin group and 13 deaths in 59 participants (22%) in the no-
treatment group at six months. At 24 months, Foy 1992 reported
10 deaths in 56 participants (18%) in the carbamazepine group,
27 deaths in 56 participants (48%) in the phenytoin group and 13
deaths in 59 participants (22%) in the no-treatment group. The
number of deaths in the phenytoin group was significantly higher
than the other treatment groups.
Phenytoin versus valproate
Beenen 1999 reported 13 deaths in 50 participants (26%) in the
phenytoin group and 10 deaths in 50 participants (20%) in the
valproate group.
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Levetiracetam versus phenytoin
Fuller 2013 reported three deaths in 39 participants (8%) in the
levetiracetam group and five deaths in 42 participants (12%) in
the phenytoin group.
Zonisamide versus phenobarbital
Nakamura 1999 reported eight deaths in 112 participants (7%)
in the zonisamide group and 13 deaths in 107 participants (12%)
in the phenobarbital group.
Summary
Overall, the quality of the evidence for this outcome was low
due to risk of bias and variability of treatment protocols in the
included trials. One trial (Foy 1992), found significantly fewer
deaths in the carbamazepine and the no-treatment group at 24
months compared to phenytoin. This trial showed no significant
difference between the interventions at six months (Analysis 1.4).
Functional outcome
No included trials reported any data or results for a functional
outcome.
Adverse effects
Eight trials, with a total of 1165 participants, reported the number
of people experiencing adverse events during the trials. See Table
3 for individual trial results and see Analysis 1.5 for comparative
results for adverse events. No adverse effects data from the two
remaining trials were provided (Foy 1992; Lee 1989).
Phenytoin versus valproate
Beenen 1999 reported that four out of 50 participants experienced
a skin reaction, three out of 50 participants experienced liver dys-
function, one out of 50 participants experienced thrombopenia,
and there was one case of nausea within the phenytoin group (N
= 50). In the valproate group there were three cases of liver dys-
function and one case of a rise in liver enzymes (N = 50). Zhang
2000 reported eight cases of rash, one case of poisoning and two
cases of liver damage in the phenytoin group, whilst in the val-
proate group, there was one case of rash and one case of mild liver
damage.
Phenytoin versus placebo or no treatment
North 1983 reported eight cases of rash, one case of involuntary
movements, one hirsutism, one headache and one case of discom-
fort of the face in the phenytoin group (N = 140) compared to one
case of rash, one dizziness and one nausea in the placebo group
(N = 141). Wu 2013 reported 11 participants with adverse effects
of treatment in the phenytoin group (N = 62) and no participants
in the NT group. The reported events included four cases of rash,
four cases of increased liver function test values, two cases each of
thrombocytopenia, confusion and aphasia, and one case each of
decreased level of consciousness, nausea, vomiting, dry itchy skin,
ataxia and photophobia.
Phenobarbital or phenytoin versus no treatment
Franceschetti 1990 reported minimal data on adverse effects, only
that three out of 10 participants in the phenytoin group and one
out of 10 participants in the phenobarbital group experienced
neurological side effects.
Levetiracetam versus phenytoin
Fuller 2013 reported that a total of 22 out of 39 people taking lev-
etiracetam experienced adverse events, eight experienced lethargy/
tiredness or asthenia, four people experienced rash, one person
had delirium, one had headache, one had pruritus and seven ex-
perienced mood/irritability problems. In the phenytoin group a
total of 18 out of 42 people experienced adverse events, with five
cases of rash/itch, three cases each of thrombophlebitis and mood/
irritability problems, two cases each of drug intoxication and ana-
phylaxis, and one case each of ataxia, nausea, and lethargy/tired-
ness/asthenia.
Iuchi 2015 reported adverse effects for the overall trial population
(N = 146) rather than the subgroup of participants with no prior
history of seizures (N = 110). In the levetiracetam group, three
participants experienced haematological toxicity, two participants
in the phenytoin group experienced haematological toxicity, two
people experienced Grade 3 hyponatraemia, two people experi-
enced Grade 3 skin eruption and two people experienced atrial
fibrillation.
Zonisamide versus phenobarbital
Nakamura 1999 reported two cases of somnolence and six cases
of nausea in the zonisamide group (N = 129), and seven cases of
somnolence and two cases of nausea in the phenobarbital group
(N = 126). Overall they reported 28 adverse effects in 129 partic-
ipants in the zonisamide group and 30 adverse effects out of 126
participants in the phenobarbital group.
Summary
Overall, the quality of the evidence for this outcome was low due
to risk of bias and variability of treatment protocols in the included
trials. Two trials (North 1983; Wu 2013) found that significantly
more adverse events were reported on phenytoin compared to
placebo or no treatment and one trial (Zhang 2000) found that
significantly more adverse events were reported in the phenytoin
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group compared with participants treated with valproate (Analysis
1.5).
D I S C U S S I O N
Summary of main results
The 10 trials included in this Cochrane Review were all RCTs in-
vestigating the effects of a range of AEDs given either immediately
before or after a craniotomy procedure to people with no previous
history of seizures or exposure to AEDs.
For the outcome of incidence of seizures, overall most trials re-
ported no significant difference between treatmentwith AEDs and
no treatment, or between treatment with different AEDs. Only
two trials reported any statistically significant findings. InLee 1989
and North 1983, the incidence of early seizures was reduced in
the AED group (phenytoin) compared to placebo (P = 0.05 and
P = 0.02 respectively). Overall, the majority of results from the
individual trials showed few significant differences between AED
treatment participants and control participants for outcomes rel-
evant to the number of deaths and adverse effects. However, one
trial (Foy 1992), showed that significantly more deaths occurred
on phenytoin than carbamazepine or no treatment at 24 months
(P = 0.001 and P = 0.005 respectively) and three trials did show
significant differences for adverse event outcomes (Fuller 2013;
Wu 2013; Zhang 2000). None of the included trials examined
participants’ functional outcomes.
Overall completeness and applicability of
evidence
The underlying pathologies for craniotomy surgery were mixed
within the trials (e.g. tumour, abscess, meningioma), with a small
percentage of participants having surgery as a result of head in-
juries. One study included a substantial proportion (210/374) of
people with head-injury (Lee 1989). This is a major limitation
of this review as the objective is to examine outcomes for people
undergoing craniotomy presenting with non-trauma pathology.
We acknowledge the possibility of differences in the risk of seizure
postsurgery depending on the underlying pathology of the partic-
ipant.
We were unable to meta-analyse any of the data and structuring
a narrative summary was difficult for a number of reasons: few
trials were available under each comparison examined (see Data
synthesis for list of comparisons under investigation) and the in-
terventions varied substantially with regards to duration of treat-
ment period, dose and method of drug administration, country,
methodological rigour and underlying pathologies. Trials differed
regarding their reporting of outcomes, one trial did not differen-
tiate between early and late seizures, and information about ad-
verse effects of treatment was very limited. Most trials had similar
inclusion and exclusion criteria. People undergoing supratentorial
craniotomy were randomised in seven of the 10 included trials,
but Fuller 2013, Iuchi 2015 and Nakamura 1999 did not specify
the type of surgery.
Quality of the evidence
The outcomes of the risk of bias assessments conducted for each
trial are noteworthy. We rated most trials as unclear on several
of the criteria due to lack of published information regarding
methodological trial design. We rated only two of the 10 trials at
low risk of bias due to the method used to generate the randomi-
sation sequence (Beenen 1999; Foy 1992), and only one trial used
adequate methods for concealing the allocation of intervention
(Beenen 1999). Most trials used adequate methods for blinding
participants and outcome assessors; however, one trial was un-
blinded (Foy 1992), and therefore we rated it at high risk of bias
for this criteria. There were no protocols available for any of the
trials, therefore assessing selective reporting across trials was rated
as unclear. We rated several trials as unclear on how they managed
missing data within their analyses. In most cases trials reported
attrition and described the reasons for withdrawal.
Furthermore, variability of treatment protocols, particularly AED
interventions examined and control groups used prevented us from
conducting data synthesis and comparison of interventions and
controls was difficult. Therefore, we rated the overall quality of
the evidence for all outcomes provided by this review to be low.
Potential biases in the review process
Wedid not identify any biases in the review process.We conducted
this review in line with Cochrane MECIR standards (MECIR
2016), and presented results in the most appropriate way possible,
given the heterogeneity of the evidence.
Agreements and disagreements with other
studies or reviews
A systematic review published in 1996 (Kuijlen 1996), assessed
the effectiveness of prophylactic AED use in people undergoing
supratentorial craniotomies. The review included three trials (Foy
1992; Lee 1989; North 1983), that were considered to be of satis-
factory methodological quality. Kuijlen 1996 calculated odds ra-
tios as a means of assessing the degree of association between treat-
ment and the incidences of convulsions. The results of pooling
the data from these three trials demonstrated no statistically sig-
nificant difference between prophylaxis with AEDs and no treat-
ment. The authors of Kuijlen 1996 noted that there were only a
small number of trials available in this area. A systematic review
published in 2017 (Islim 2017), assessed the use of prophylactic
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AEDs for people undergoing surgery for meningioma. It included
11 cohort trials (1143 participants) and the authors reported that
there was no statistically significant difference between prophy-
laxis with AEDs and no treatment. They advised that good-quality
RCTs are needed for robust conclusions to be drawn.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Our results from this review show that there is not enough evi-
dence of sufficient quality available to suggest that antiepileptic
drug (AED) treatment can or cannot be recommended to reduce
postcraniotomy seizures. There is no evidence on which to base
clinical practice.
Implications for research
More trials are needed to better evaluate the effectiveness of pro-
phylactic treatment with AEDs in preventing seizures following
cranial surgery. These trialsmust address themethodological weak-
nesses and protocol inconsistencies we identified within this re-
view including:
1. timing of AED administration (pre- or postsurgery);
2. adequate length of treatment and follow-up period
3. head-to-head or other control group;
4. methodological aspects (well-controlled trials with adequate
methods employed for generating randomisation sequences and
concealing allocation); and
5. outcome reporting (differentiating between early and late
seizures, adverse effects of treatment, handling of missing data)
or other important outcomes (functional outcomes in terms of
activities of daily living including working, driving etc.) not
currently addressed.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Beenen 1999
Methods Randomised double-blind, placebo-controlled, single-centre (Netherlands), parallel trial
2 treatment arms: PHT and VAL
Allocation concealed using sealed envelopes, trial medication identical in pre-coded
packaged materials
Treatment period: 12 months
Follow up: 12 months
Participants Adults aged 21-78 (mean age in PHT arm = 55 years, mean age in VAL arm = 51
years) Overall 47 men and 53 women, all patients undergoing craniotomy for different
pathological conditions. Participants were not taking AEDs prior to randomisation and
had no history of seizures
100 randomised: 50 to PHT and 50 to VAL
Interventions Group 1: PHT 100 mg (IV) 3 times daily administered immediately postoperation in
recovery room
Group 2: VAL 500 mg (IV) 3 times daily administered immediately postoperation in
recovery room
Participants took medication in oral form as soon as was possible for 12 months
Outcomes Primary outcome: drug efficacy (time of and number of seizures)
Secondary outcomes: tolerability (number of withdrawals, adverse effects), death, QoL
and cognitive functioning
Notes ITT analysis employed for primary outcome, not for other outcomes (QoL)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Study used computer-generated randomi-
sation method
Allocation concealment (selection bias) Low risk Sealed envelopes, pre-coded and packaged
medication
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Adequate blinding techniques used for per-
sonnel and participants
Incomplete outcome data (attrition bias)
All outcomes
Low risk Study attrition reported, employed ITT
analysis for primary outcome
Selective reporting (reporting bias) Unclear risk No trial protocol available
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Beenen 1999 (Continued)
Other bias Low risk No other bias detected
Foy 1992
Methods Randomised, controlled, parallel, single-centre (UK) trial
5 treatment arms: CBZ 6 months and 24 months, PHT 6 months and 24 months, no
treatment
Participants randomised in blocks of 5 from prepared lists
Treatment period: 6 or 24 months
Follow up: 3 to 8 years
Participants Patients aged 16-77 years (median 45 years), 134 men and 142 women all undergoing
supratentorial craniotomy. Participants had no previous history of seizures
276 randomised: 50 to CBZ (6months), 56 toCBZ (24months), 55 to PHT (6months)
, 56 to PHT (24 months), 59 to no treatment
Interventions Group 1: CBZ 200 mg/6 h for 24 h pre-surgery, 200 mg/8 h thereafter for 6 months
Group 2: CBZ 200 mg/6 h for 24 h pre-surgery, 200 mg/8 h thereafter for 24 months
Group 3: PHT 15 mg/kg 24 h pre-surgery, 100 mg/8 h thereafter for 6 months
Group 4: PHT 15 mg/kg 24 h pre-surgery, 100 mg/8 h thereafter for 24 months
Group 5: no treatment
Outcomes Primary outcome: drug efficacy (number of seizures)
Secondary outcomes: seizure freedom, death
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Used blocks of 5 from prepared lists
Allocation concealment (selection bias) Unclear risk No details in text
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Trial was unblinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Study attrition reported, however, missing
data and ITT analysis is unclear within the
text
Selective reporting (reporting bias) Unclear risk No trial protocol available
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Foy 1992 (Continued)
Other bias Unclear risk The first 102 patients were randomised to
treatment with CBZ or PHT for 6 or 24
months. Since analysis showed little dif-
ference in the incidence of postoperative
seizures in this group relative to a retrospec-
tive study of postoperative seizures, the sub-
sequent patients were randomised equally
betweenpolicies of no treatment, treatment
with CBZ and treatment with PHT
Franceschetti 1990
Methods Randomised, controlled parallel trial, single centre trial.
2 treatment arms, one no treatment arm
No details available in text of randomisation or blinding methods employed
Treatment period: unclear
Follow up: >6months to <12 months
Participants Mean age 55 years, 34 men and 29 women undergoing supratentorial craniotomy for
neoplasms
128 patients entered trial
Group A: 65 participants had pre-operative seizures and were treated with AEDs (ex-
cluded from this review)
Group B: 63 participants had no seizures prior to operation and were not taking any
AEDs
Interventions 3 treatment arms for Group B randomised participants: PB, PHT and no treatment
Group 1: PB (4 mg/kg daily for 5 days), followed by 2 mg/kg daily
Group 2: PHT (10 mg/kg daily for 5 days), followed by 5 mg/kg daily
Group 3: no treatment
Outcomes Primary outcomes: efficacy (number of seizures (early and late seizures), adverse effects
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details in text
Allocation concealment (selection bias) Unclear risk No details in text
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No details in text
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Franceschetti 1990 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Attrition unreported, 24 participants with
missing data for late seizure outcome
Selective reporting (reporting bias) Unclear risk No trial protocol available
Other bias Low risk No other bias detected
Fuller 2013
Methods Pragmatic, prospective, randomised, single-centre (Australia) trial
2 treatment arms: LEV or PHT
Block randomisation
Treatment period: 90 days
Follow up: 90 days
Participants Patients aged 25-89 years with neurosurgical indications requiring craniotomy for which
perioperative IV seizure prophylaxis was routine or otherwise warranted. Participants
must have been on no AED or stable dose AED(s) excluding study AEDs for 3 weeks
before enrolment, and must not have contraindication to either study medication
81 randomised: 39 to LEV, 42 to PHT
Interventions Group 1: LEV 250-500 mg daily IV or orally
Group 2: PHT 300 mg (≤ 3 doses in 24 h) or 1000 mg (single dose) IV loading then
300 mg daily IV or orally
≤ 2 oral doses of allocated AEDs were allowed between randomisation and IV admin-
istration. 1 pre-operative IV dose was required. Following IV AED administration, par-
ticipants received the same medication orally. Additional PHT titration to therapeutic
serum levels was allowed but not mandated. Doses were within standard range. After
randomisation, treating teams made all decisions regarding study AED treatment in-
cluding IV and oral durations, serologic monitoring, dose adjustment and cessation
Outcomes Primary outcome: discontinuation of study AED because of side effects
Secondary outcome: seizure occurrence
Outcomes reported at 3 days and 90 days
Notes Not ITT analysis. The pragmatic nature of the trial is highlighted. The reviewers also
note the length of active treatment in the trial. 4 people in the trial had prior seizures
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Methods of sequence generation not de-
scribed. Block randomisation was reported
as used. However, the paper reports that
early during data collection the contrac-
tor communicated that “allocation was as
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Fuller 2013 (Continued)
follows: each 10 sequentially recruited pa-
tients were not internally randomised but
received the same drug, determined by hat-
draw at enrolment of the first patient in
each block, with eight blocks of 10 patients
then two blocks of four to be randomised
with equal probability.” At study comple-
tion, impact of allocation procedure on bias
was assessed by statistical comparison of
baseline patient characteristics, with simi-
lar age and gender distribution and propor-
tion of serious pathologies and death from
underlying pathology found between treat-
ment groups
Allocation concealment (selection bias) Unclear risk The allocation procedure was communi-
cated to quarantined keeper for randomi-
sation data. However, it is unclear what the
procedure was. Also, see above note as to
failure of block randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The investigation team conducting the in-
formation and consentingprocess, data col-
lection, outcome adjudication and analy-
sis was blinded. The quarantined keeper
and liaison for randomisation data did not
participate in recruitment, patient treat-
ment, data collection, outcome assessment
or analysis. Recruitingneurosurgical teams,
including anaesthetists, were blinded to the
allocation procedure. Otherwise the study
was open-label
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk ITT analysis not used. 81 people ran-
domised, 74 were included in the analyses
at 3 days and 61 at 90 days
Selective reporting (reporting bias) Unclear risk No trial protocol available
Other bias Low risk UCB Pharma provided funding and LEV
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Iuchi 2015
Methods Randomised, prospective, parallel, single-centre (Japan) trial
2 treatment arms: LEV or PHT
Patients were randomised using sequentially numbered envelopes
Treatment period: 7 days. No further follow-up
Participants Patients aged ≥ 16 years with supratentorial tumours that required craniotomy. The
history of seizures prior to surgery was not considered, but patients were excluded if they
had a history of seizures and their seizures remained after medication with LEV or PHT.
No known allergy to study treatments
147 randomised: 73 to LEV, 74 to PHT
A subgroup of participants (N = 110) had no prior history of seizures
Interventions In participants who had a history of seizures prior to surgery, and who received AEDs to
control seizures, AEDs were continued until the day before surgery
Group 1: LEV 500 mg (initially by suppository and then orally) every 12 h
Group 2: PHT 15-18 mg IV after induction of anaesthesia and continued at 5-7.5 mg
per day. After participants were able to take oral medication, PHT was administered at
250 mg daily. This dose was sufficient to achieve a therapeutic plasma concentration in
Japanese participants
Plasma concentrations of all participants were measured 2 h after the first administration
of study drug
Outcomes Primary outcome: occurrence of seizures
Secondary outcomes: occurrence of haematological and non-haematological adverse
events
Notes The overall trial population (N = 147) included participants with and without a history
of seizures. The results for participants with no history of seizures (N = 110) is reported
as a subgroup analysis
The trial authors note that the plasma concentration of participants taking PHT were at
the lower limit of the therapeutic range. They also note that plasma concentration did
not differ between participants who experienced and did not experience postoperative
seizures
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Individual randomised allocation was per-
formed using sequentially numbered en-
velopes. It is not stated if the envelopes were
opaque or sealed
Allocation concealment (selection bias) Unclear risk Individual randomised allocation was per-
formed using sequentially numbered en-
velopes. It is not stated if the envelopes were
opaque or sealed
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Iuchi 2015 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The trial was unblinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk One participant was excluded from the
analysis as the lesion was found to be non-
neoplastic
Selective reporting (reporting bias) Unclear risk No study protocol is available.
Other bias Low risk None identified
Lee 1989
Methods Randomised, double-blind, placebo-controlled trial
2 treatment arms: PHT and placebo
Patients randomised using random digits, all participants received identical medication
Treatment period: 3 days. No follow-up of participants
Participants Adults, mean age 39.9 years (PHT) and 37.5 years (placebo) all undergoing intracranial,
supratentorial surgery. Participants had no history of seizures and not taking AEDs prior
to surgery
400 participants randomised: 189 to PHT and 185 to placebo. 26 died prior to treatment
Interventions Group 1: PHT 15 mg/kg for 15-20 min prior to wound closure followed by 5-6 mg/kg/
day, 3 times daily in first 3 postoperative days
Group 2: saline solution administered as described above
Outcomes Primary outcome: efficacy (number of seizures at 3 days)
Notes 26 participants randomised died prior to treatment, excluded from all data exploration
and analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Used random digits, unclear how gener-
ated, whether open list, etc
Allocation concealment (selection bias) Unclear risk No details in text
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical medication used for both groups.
Adequate blindingmethods for key person-
nel and participants
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Lee 1989 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear details on study attrition rate and
how data analysed
Selective reporting (reporting bias) Unclear risk No protocol available
Other bias Low risk No other bias detected
Nakamura 1999
Methods Randomised, double-blind, controlled, multi-centre (Japan) trial
2 treatment arms: ZNS and PB.
Identical medication administered (no details of methods of randomisation)
Treatment period: 1 year. Follow-up period: 3 years
Participants 278 patients who were scheduled to receive craniotomy for cerebral tumours, cerebrovas-
cular diseases and head trauma, were randomised
129 in ZNS group analysed, 126 in PB group were analysed
Interventions Group 1: ZNS (100 mg twice daily) until 1 month after craniotomy
Group 2: PB (40 mg twice daily) until 1 month after craniotomy
In both groups dose was adjusted to therapeutic serum concentration and continued up
to 1 year
Outcomes Primary outcome: frequency of epilepsy
Secondary outcome: drug concentration, adverse effects.
Notes 23 ’unsuitable cases’ not included in the analysis. 36 cases not followed up for full 3 years
of the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details in text
Allocation concealment (selection bias) Unclear risk No details in text
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical medication administered to both
groups. Drug name blinded from partici-
pating institutions, only blood concentra-
tion values provided
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 23 cases not included within analysis, all
excluded prior to treatment. 36 lost to fol-
low-up were included in analysis
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Nakamura 1999 (Continued)
Selective reporting (reporting bias) Unclear risk Trial reports data for overall adverse effects,
only reports data for 2 individual adverse
effects
Other bias Low risk No other bias detected
North 1983
Methods Randomised, double-blinded, placebo-controlled, parallel, single-centre (Australia) trial
2 treatment arms: PHT and placebo
Participants received identical medication (no details available of randomisation meth-
ods)
Treatment period: 12 months
Follow up: 12 months
Participants Adults, mean age 46.7 years (PHT) and 50.21 years (placebo), all undergoing supra-
tentorial craniotomy. Participants had no previous exposure to AEDs and no previous
history of epilepsy
281 patients were randomised: 140 to PHT and 141 to placebo
Interventions Group 1: PHT 250 mg twice daily administered (IV) first dose administered in the
recovery room postcraniotomy followed by oral medication 100 mg 3 times daily for 12
months
Group 2: placebo medication administered as described above.
Outcomes Primary outcome: efficacy (number of seizures)
Secondary outcomes: survival time (number of days since randomisation to incidence of
seizure or to 365 days in seizure-free participants), adverse effects
Notes 63 participants in PHT arm and 59 participants in placebo arm received intended
treatment. All cases randomised were analysed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details in text
Allocation concealment (selection bias) Unclear risk No details in text
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical medication used for both groups.
Only pharmacologist aware of serum drug
levels and both PHT and placebo group
participants had blood samples taken
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North 1983 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition reported and ITT analysis em-
ployed. 6 participants lost to follow-up
Selective reporting (reporting bias) Unclear risk Protocol outlined within paper. All out-
comes reported. Full protocol not available
Other bias Low risk No other bias detected
Wu 2013
Methods Prospective RCT. Single-centre (USA) trial
2 study arms: PHT and no treatment
Treatment period: 7 days at full dose followed by tapering
Follow up: up to 12 months
Participants Patients aged 16-84, mean age 56 years (PHT) and 61 years (no treatment) with intra-
parenchymal supratentorial brain tumours either proven by biopsy to be a brain metas-
tasis or a glioma, or with compelling CT or MRI evidence of metastasis or glioma. All
participants had to be previously untreated with AEDs
123 randomised: 62 to PHT and 61 to no treatment
Interventions Group 1: PHT 100 mg every 8 h administered IV or oral
Group 2: no treatment
Outcomes Primary outcomes: seizure occurrence
Secondary outcomes: adverse reactions to PHT
Notes Measurements taken every 2-3 months up to 12 months. Time points reported in study
were 7 days and 30 days. Trial was stopped early due to few events
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Only outcome assessment was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Unclear risk Study protocol not available
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Wu 2013 (Continued)
Other bias Unclear risk Trial stopped early due to futility, unclear
if this introduced bias
Zhang 2000
Methods Prospective RCT (China)
2 treatment arms: PHT and VAL
Treatment period: 1 month
Follow up: 3 months
Participants 152 patients undergoing craniotomy surgery for differing pathologies and who had no
prior history of seizures or AED use. Participants in the PHT group (N = 72) had a
mean age of 47.98 ± 9.67 and participants in the VAL group (N = 80) had a mean age
of 46.15 ± 9.54
Interventions Group 1: before surgery, oral PHT 10 mg/kg given 3 times a day for 7 days (plasma PHT
concentration was then checked); after surgery, IV PHT 5 mg/kg given 3 times daily for
2 consecutive days, and then from third postoperative day onwards, a maintenance dose
of oral PHT 5 mg/kg given 3 times daily for a month.
Group 2: before surgery, oral 30 mg/kg VAL given 3 times daily; after surgery, IV 20 mg/
kg VAL given three times daily for 2 consecutive days, and then from third postoperative
day onwards, a maintenance dose of oral 20 mg/kg VAL given twice daily for a month
Outcomes The primary objective was to compare the effects of PHT and VAL on postoperative
epilepsy and toxicity, as well as the relationship with blood concentration
Notes No information available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information given
Allocation concealment (selection bias) Unclear risk No information given
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information given
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information given
Selective reporting (reporting bias) Unclear risk No information given
31Antiepileptic drugs as prophylaxis for postcraniotomy seizures (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Zhang 2000 (Continued)
Other bias Unclear risk Insufficient information to make a judge-
ment
AED: antiepileptic drug
CBZ: carbamazepine
CT: computerised tomography
h: hour
IV: intravenously
ITT: intention-to-treat
LEV: levetiracetam
MRI: magnetic resonance imaging
PB: phenobarbital
PHT: phenytoin
QoL: quality of life
RCT: randomised controlled trial
VAL: valproate
ZNS: zonisamide
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Baker 1995 Not a RCT, retrospective trial
Boarini 1985 Not a RCT, retrospective trial
De Santis 1996 Not a RCT
De Santis 2002 Participants taking AEDs prior to randomisation
Grobelny 2009 Not a RCT, retrospective design
Hayashi 1999 Not a RCT
Levati 1996 Participants taking AEDs prior to randomisation
Lim 2009 Participants taking AEDs and experiencing seizures prior to randomisation
Manaka 2003 Review paper
Murri 1992 Not a RCT
Notani 1984 Not a RCT
32Antiepileptic drugs as prophylaxis for postcraniotomy seizures (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Shaw 1991 Review paper
Temkin 1990 No craniotomy surgery performed. People with brain injury
Temkin 1999 No craniotomy surgery performed. People with brain injury
Tsolaki 1987 Participants taking AEDs prior to study
AED: antiepileptic drug
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Antiepileptic drugs as prophylaxis for postcraniotomy seizures
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All seizures 10 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Phenytoin (intervention)
vs valproate (comparator)
2 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Carbamazepine
(intervention) vs phenytoin
(comparator) for 6 months
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Carbamazepine
(intervention) vs phenytoin
(comparator) for 24 months
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 Carbamazepine
(intervention) vs no treatment
(comparator) for 6 months
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.5 Carbamazepine
(intervention) vs no treatment
(comparator) for 24 months
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.6 Phenytoin (intervention)
vs no treatment (comparator)
for 6 months
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.7 Phenytoin (intervention)
vs no treatment (comparator)
for 24 months
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.8 Phenobarbital or
phenytoin (intervention) vs no
treatment (comparator)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.9 Levetiracetam
(intervention) vs phenytoin
(comparator)
2 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.10 Phenytoin (intervention)
vs placebo or no treatment
(comparator)
3 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.11 Zonisamide
(intervention) vs phenobarbital
(comparator)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Early seizures 9 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Phenytoin (intervention)
vs valproate (comparator)
2 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Phenobarbital or
phenytoin (intervention) vs no
treatment (comparator)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Levetiracetam
(intervention) vs phenytoin
(comparator)
2 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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2.4 Phenytoin (intervention)
vs placebo or no treatment
(comparator)
3 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.5 Zonisamide (intervention)
vs phenobarbital (comparator)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Late seizures 4 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Phenytoin (intervention)
vs valproate (comparator)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Phenytoin (intervention)
vs placebo or no treatment
(comparator)
2 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Zonisamide (intervention)
vs phenobarbital (comparator)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Deaths 5 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 Phenytoin (intervention)
vs valproate (comparator)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Carbamazepine
(intervention) vs phenytoin
(comparator) for 6 months
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 Carbamazepine
(intervention) vs phenytoin
(comparator) for 24 months
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.4 Carbamazepine
(intervention) vs no treatment
(comparator) for 6 months
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.5 Carbamazepine
(intervention) vs no treatment
(comparator) for 24 months
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.6 Phenytoin (intervention)
vs no treatment (comparator)
for 6 months
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.7 Phenytoin (intervention)
vs no treatment (comparator)
for 24 months
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.8 Levetiracetam
(intervention) vs phenytoin
(comparator)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.9 Phenytoin (intervention)
vs placebo (comparator)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.10 Zonisamide
(intervention) vs phenobarbital
(comparator)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Adverse events 8 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5.1 Phenytoin (intervention)
vs valproate (comparator)
2 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Phenobarbital
(intervention) vs phenytoin
(comparator)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.3 Levetiracetam
(intervention) vs phenytoin
(comparator)
2 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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5.4 Phenytoin (intervention)
vs placebo or no treatment
(comparator)
2 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.5 Zonisamide (intervention)
vs phenobarbital (comparator)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Analysis 1.1. Comparison 1 Antiepileptic drugs as prophylaxis for postcraniotomy seizures, Outcome 1 All
seizures.
Review: Antiepileptic drugs as prophylaxis for postcraniotomy seizures
Comparison: 1 Antiepileptic drugs as prophylaxis for postcraniotomy seizures
Outcome: 1 All seizures
Study or subgroup Intervention Comparator Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Phenytoin (intervention) vs valproate (comparator)
Beenen 1999 7/50 7/50 1.00 [ 0.38, 2.64 ]
Zhang 2000 6/72 9/80 0.74 [ 0.28, 1.98 ]
2 Carbamazepine (intervention) vs phenytoin (comparator) for 6 months
Foy 1992 21/50 22/55 1.05 [ 0.66, 1.66 ]
3 Carbamazepine (intervention) vs phenytoin (comparator) for 24 months
Foy 1992 20/56 16/56 1.25 [ 0.73, 2.15 ]
4 Carbamazepine (intervention) vs no treatment (comparator) for 6 months
Foy 1992 21/50 25/59 0.99 [ 0.64, 1.54 ]
5 Carbamazepine (intervention) vs no treatment (comparator) for 24 months
Foy 1992 20/56 25/59 0.84 [ 0.53, 1.34 ]
6 Phenytoin (intervention) vs no treatment (comparator) for 6 months
Foy 1992 22/55 25/59 0.94 [ 0.61, 1.47 ]
7 Phenytoin (intervention) vs no treatment (comparator) for 24 months
Foy 1992 16/56 25/59 0.67 [ 0.40, 1.12 ]
8 Phenobarbital or phenytoin (intervention) vs no treatment (comparator)
Franceschetti 1990 6/41 7/22 0.46 [ 0.18, 1.20 ]
9 Levetiracetam (intervention) vs phenytoin (comparator)
Fuller 2013 0/39 6/42 0.08 [ 0.00, 1.42 ]
Iuchi 2015 1/53 8/58 0.14 [ 0.02, 1.06 ]
10 Phenytoin (intervention) vs placebo or no treatment (comparator)
Lee 1989 2/189 9/185 0.22 [ 0.05, 0.99 ]
North 1983 18/140 26/141 0.70 [ 0.40, 1.21 ]
0.01 0.1 1 10 100
Favours intervention Favours comparator
(Continued . . . )
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(. . . Continued)
Study or subgroup Intervention Comparator Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wu 2013 15/62 11/61 1.34 [ 0.67, 2.68 ]
11 Zonisamide (intervention) vs phenobarbital (comparator)
Nakamura 1999 13/129 11/126 1.15 [ 0.54, 2.48 ]
0.01 0.1 1 10 100
Favours intervention Favours comparator
Analysis 1.2. Comparison 1 Antiepileptic drugs as prophylaxis for postcraniotomy seizures, Outcome 2
Early seizures.
Review: Antiepileptic drugs as prophylaxis for postcraniotomy seizures
Comparison: 1 Antiepileptic drugs as prophylaxis for postcraniotomy seizures
Outcome: 2 Early seizures
Study or subgroup Intervention Comparator Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Phenytoin (intervention) vs valproate (comparator)
Beenen 1999 4/50 2/50 2.00 [ 0.38, 10.43 ]
Zhang 2000 6/72 9/80 0.74 [ 0.28, 1.98 ]
2 Phenobarbital or phenytoin (intervention) vs no treatment (comparator)
Franceschetti 1990 3/41 4/22 0.40 [ 0.10, 1.64 ]
3 Levetiracetam (intervention) vs phenytoin (comparator)
Fuller 2013 0/39 6/42 0.08 [ 0.00, 1.42 ]
Iuchi 2015 1/53 8/58 0.14 [ 0.02, 1.06 ]
4 Phenytoin (intervention) vs placebo or no treatment (comparator)
Lee 1989 2/189 9/185 0.22 [ 0.05, 0.99 ]
North 1983 4/140 14/141 0.29 [ 0.10, 0.85 ]
Wu 2013 2/62 5/61 0.39 [ 0.08, 1.95 ]
5 Zonisamide (intervention) vs phenobarbital (comparator)
Nakamura 1999 6/129 3/126 1.95 [ 0.50, 7.64 ]
0.01 0.1 1 10 100
Favours intervention Favours comparator
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Analysis 1.3. Comparison 1 Antiepileptic drugs as prophylaxis for postcraniotomy seizures, Outcome 3
Late seizures.
Review: Antiepileptic drugs as prophylaxis for postcraniotomy seizures
Comparison: 1 Antiepileptic drugs as prophylaxis for postcraniotomy seizures
Outcome: 3 Late seizures
Study or subgroup Intervention Comparator Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Phenytoin (intervention) vs valproate (comparator)
Beenen 1999 3/50 5/50 0.60 [ 0.15, 2.38 ]
2 Phenytoin (intervention) vs placebo or no treatment (comparator)
North 1983 14/140 12/141 1.18 [ 0.56, 2.45 ]
Wu 2013 13/62 6/61 2.13 [ 0.87, 5.25 ]
3 Zonisamide (intervention) vs phenobarbital (comparator)
Nakamura 1999 7/129 8/126 0.85 [ 0.32, 2.29 ]
0.01 0.1 1 10 100
Favours intervention Favours comparator
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Analysis 1.4. Comparison 1 Antiepileptic drugs as prophylaxis for postcraniotomy seizures, Outcome 4
Deaths.
Review: Antiepileptic drugs as prophylaxis for postcraniotomy seizures
Comparison: 1 Antiepileptic drugs as prophylaxis for postcraniotomy seizures
Outcome: 4 Deaths
Study or subgroup Intervention Comparator Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Phenytoin (intervention) vs valproate (comparator)
Beenen 1999 13/50 10/50 1.30 [ 0.63, 2.68 ]
2 Carbamazepine (intervention) vs phenytoin (comparator) for 6 months
Foy 1992 9/50 15/55 0.66 [ 0.32, 1.37 ]
3 Carbamazepine (intervention) vs phenytoin (comparator) for 24 months
Foy 1992 10/56 27/56 0.37 [ 0.20, 0.69 ]
4 Carbamazepine (intervention) vs no treatment (comparator) for 6 months
Foy 1992 9/50 13/59 0.82 [ 0.38, 1.75 ]
5 Carbamazepine (intervention) vs no treatment (comparator) for 24 months
Foy 1992 10/56 13/59 0.81 [ 0.39, 1.70 ]
6 Phenytoin (intervention) vs no treatment (comparator) for 6 months
Foy 1992 15/55 13/59 1.24 [ 0.65, 2.36 ]
7 Phenytoin (intervention) vs no treatment (comparator) for 24 months
Foy 1992 27/56 13/59 2.19 [ 1.26, 3.80 ]
8 Levetiracetam (intervention) vs phenytoin (comparator)
Fuller 2013 3/39 5/42 0.65 [ 0.17, 2.53 ]
9 Phenytoin (intervention) vs placebo (comparator)
North 1983 20/140 24/141 0.84 [ 0.49, 1.45 ]
10 Zonisamide (intervention) vs phenobarbital (comparator)
Nakamura 1999 8/112 13/107 0.59 [ 0.25, 1.36 ]
0.01 0.1 1 10 100
Favours intervention Favours comparator
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Analysis 1.5. Comparison 1 Antiepileptic drugs as prophylaxis for postcraniotomy seizures, Outcome 5
Adverse events.
Review: Antiepileptic drugs as prophylaxis for postcraniotomy seizures
Comparison: 1 Antiepileptic drugs as prophylaxis for postcraniotomy seizures
Outcome: 5 Adverse events
Study or subgroup Intervention Comparator Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Phenytoin (intervention) vs valproate (comparator)
Beenen 1999 9/50 4/50 2.25 [ 0.74, 6.83 ]
Zhang 2000 11/72 2/80 6.11 [ 1.40, 26.65 ]
2 Phenobarbital (intervention) vs phenytoin (comparator)
Franceschetti 1990 1/15 3/10 0.22 [ 0.03, 1.85 ]
3 Levetiracetam (intervention) vs phenytoin (comparator)
Fuller 2013 22/39 18/42 1.32 [ 0.84, 2.05 ]
Iuchi 2015 3/73 8/73 0.38 [ 0.10, 1.36 ]
4 Phenytoin (intervention) vs placebo or no treatment (comparator)
North 1983 12/140 3/141 4.03 [ 1.16, 13.97 ]
Wu 2013 11/62 0/61 22.63 [ 1.36, 375.83 ]
5 Zonisamide (intervention) vs phenobarbital (comparator)
Nakamura 1999 28/129 30/126 0.91 [ 0.58, 1.43 ]
0.01 0.1 1 10 100
Favours intervention Favours comparator
A D D I T I O N A L T A B L E S
Table 1. Comparison of treatment protocols
Study Interven-
tion and daily
dose (N)
Comparator
(s) and daily
dose (N)
Time of ad-
ministration
(reoperation/
postopera-
tion)
Treatment
duration
Mea-
surement pe-
riod reported
- early
Mea-
surement pe-
riod reported
- late
Analysis
Beenen 1999 PHT 300 mg
(N = 50)
VAL 1500
mg/day
(N = 50)
Post-op 12 months 1 week 2 weeks to 12
months
ITT
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Table 1. Comparison of treatment protocols (Continued)
Foy 1992 PHT 300 mg
6-months
(N = 55)
24-months (N
= 56)
CBZ 600 mg
6 months
(N = 50)
24 months
(N = 56)
No treatment
(N = 59)
Pre-op
and post-op
(pre- and post-
op doses dif-
fered)
6 months
24 months
Not reported 4 years (me-
dian)
ITT
Franceschetti
1990
PHT 5 mg/kg
(N = 16)
PB 2 mg/kg
(N = 25)
No treatment
(N = 22)
Pre-op
and post-op
(pre- and post-
op doses dif-
fered)
Unclear 1 week Unclear No ITT
24 partic-
ipants lost to
follow-up (for
late seizure)
Fuller 2013 LEV 250-500
mg daily
(N = 39)
PHT 300 mg
daily
(N = 42)
Pre-op
and post-op
90 days 3 days 90 days Not ITT
Only partici-
pants re-
ceiving 1 dose
were analysed
Iuchi 2015 LEV 500 mg
daily
(no prior
seizure sub-
group = 52)
PHT 15-
18 mg/kg IV
daily and 250
mg single oral
dose
(no prior
seizure sub-
group = 58)
Af-
ter anaesthesia
induction and
post-op
7 days 7 days Not measured Not ITT.
1 participant
was excluded
from the anal-
ysis
postrandomi-
sation. Lesion
was found to
be not neo-
plastic
Lee 1989 PHT 5-6 mg/
kg
(N = 189)
Placebo
(N = 185)
Pre-op
and post-op
(pre- and post-
op doses dif-
fered)
3 days 3 days Not measured ITT unclear
Randomised =
400 but 26
deaths prior to
treatment
Nakamura
1999
ZNS 200 mg
(N = 129)
PB 80 mg
(N = 126)
Pre-op
and post-op
(doses
changed
across course
of trial)
12 months Not reported 1-12 months ITT for 255
par-
ticipants who
received treat-
ment
23 ran-
domised par-
ticipants were
excluded prior
to treatment
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Table 1. Comparison of treatment protocols (Continued)
North 1983 PHT 300 mg
(N = 140)
Placebo
(N = 141)
Post-op 12 months 1 week 12 months ITT
Wu 2013 PHT 300 mg
(N = 62)
No treatment
(N = 61)
Pre-op
and post-op
7 days 7 days > 30 days ITT
Zhang 2000 PHT 10 mg/
kg 3 x daily
(oral) or 5 mg/
kg IV
(N = 72)
VAL
30 mg/kg 3 x
daily (oral) or
20 mg/kg (IV)
(N = 80)
Pre-op
and post-op
1 month 7 days > 3 months ITT
unclear Num-
bers included
in final anal-
yses not re-
ported
CBZ: carbamazepine
ITT: intention-to-treat
LEV: levetiracetam
PB: phenobarbital
PHT: phenytoin
VAL: valproate
ZNS: zonisamide
Table 2. Study results for seizure data
Trial All seizuresa Early seizuresa Late seizuresa
AED 1 AED 2 NT or
placebo
AED 1 AED 2 NT or
placebo
AED 1 AED 2 NT or
placebo
Beenen
1999
b (PHT vs
VAL)
PHT: 7/50
(14%)
VAL: 7/50
(14%)
- PHT: 4/50
(8%)
VAL: 2/50
(4%)
- PHT: 3/50
(6%)
VAL: 5/50
(10%)
-
Foy 1992b
(CBZ
vs PHT vs
NT for 6
months)
CBZ: 21/
50
(42%)
PHT: 21/
55 (38%)
NT: 25/59
(42%)
NR NR - NR NR -
Foy 1992b
(CBZ
vs PHT vs
NT for 24
months)
CBZ: 20/
56 (36%)
PHT: 16/
56 (29%)
NT: 25/59
(42%)
NR NR - NR NR -
Franceschetti
1990c (PB
Total in the PB and PHT
groups: 6/41 (15%)
NT: 7/22
(32%)
Total in the PB and PHT
groups: 3/41 (17%)
NT: 4/22
(18%)
PB 2/15
(13%)
PHT 1/10
(10%)
NT: 3/14
(21%)
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Table 2. Study results for seizure data (Continued)
vs PHT vs
NT)
Fuller
2013 (LEV
vs PHT)
LEV: 0/39
(0%)
PHT: 6/42
(14%)
- LEV: 0/39
(0%)
PHT: 6/42
(14%)
- NR NR -
Iuchi 2015
(LEV vs
PHT)
LEV: 1/53
(2%)
PHT: 8/58
(14%)
- LEV: 1/53
(2%)
PHT: 8/58
(14%)
- NR NR -
Lee 1989
b (PHT vs
placebo)
PHT: 2/
189 (1%)
- Placebo: 9/
185
(5%)
PHT: 2/
189 (1%)
Placebo: 9/
185 (5%)
NR NR -
Nakamura
1999
c (ZNS vs
PB)
ZNS: 13/
129 (10%)
PB: 11/
126 (9%)
- ZNS: 6/
129 (5%)
PB: 3/126
(2%)
- ZNS: 7/
129
(5%)
PB: 8/126
(6%)
-
North
1983
b (PHT vs
placebo)
PHT: 18/
140
(13%)
- Placebo:
26/141
(18%)
PHT: 4/
140
(3%)
- Placebo:
14/141
(10%)
PHT: 14/
140 (10%)
Placebo:
12/141
(9%)
Wu 2013
(PHT vs
NT)
PHT: 15/
62 (24%)
- NT: 11/61
(18%)
PHT: 2/62
(3%)
- NT: 5/61
(8%)
PHT: 13/
62
(21%)
- NT: 6/61
(10%)
Zhang
2000
(PHT vs
VAL)
PHT: 6/72
(8%)
VAL: 9/80
(11%)
- PHT: 6/72
(8%)
VAL: 9/80
(11%)
- NR NR
AED: antiepileptic drug; CBZ: carbamazepine; LEV: levetiracetam; NR: not reported; NT: no treatment; PB: phenobarbital; PHT:
phenytoin; VAL: valproate; ZNS: zonisamide
aSee Analysis 1.1 for comparative results for all seizures, Analysis 1.2 for early seizures and Analysis 1.3 for late seizures.
bResults from these trials reported the number of participants who had seizures out of the number of participants randomised. However
loss to follow-up during the trial was unclear.
cResults from the trials only reported the number of participants who had seizures out of the number of participants who were followed
up. Foy 1992 followed up 39 participants for late seizures. Franceschetti 1990 reported combination of PB and PHT results, it is not
possible to differentiate between groups on seizure outcome for all seizures and early seizures.
43Antiepileptic drugs as prophylaxis for postcraniotomy seizures (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 3. Results for deaths and adverse events
Trial Deathsa Adverse eventsa
AED 1 AED 2 NT or placebo AED 1 AED 2 NT or placebo
Beenen 1999b
(PHT vs VAL)
PHT: 13/50
(26%)
VAL: 10/50
(20%)
- PHT: 9/50
(18%)
VAL: 4/50 (8%) -
Foy 1992b (CBZ
vs PHT vs NT
for 6 months)
CBZ: 9/50
(18%)
PHT: 15/55
(27%)
NT: 13/59
(22%)
NR NR NR
Foy 1992b (CBZ
vs PHT vs NT
for 24 months)
CBZ: 10/56
(18%)
PHT: 27/56
(48%)
NT: 13/59
(22%)
NR NR NR
Franceschetti
1990c (PB vs
PHT vs NT)
NR NR NR PB: 1/15 (7%) PHT: 3/10
(30%)
NR
Fuller 2013
(LEV vs PHT)
LEV: 3/39 (8%) PHT: 5/42
(12%)
- LEV: 22/39
(56%)
PHT: 18/42
(43%)
-
Iuchi 2015 (LEV
vs PHT)
NR NR - LEV: 3/73 (4%) PHT: 8/73
(11%)
-
Lee 1989b (PHT
vs placebo)
NR NR - NR NR -
Nakamura 1999
c (ZNS vs PB)
ZNS: 8/112
(7%)
PB: 13/107
(12%)
- ZNS: 28/129
(22%)
PB: 30/126
(24%)
-
North
1983b (PHT vs
placebo)
PHT: 20/140
(14%)
- Placebo: 24/141
(17%)
PHT: 12/140
(9%)
Placebo: 3/141
(2%)
Wu 2013 (PHT
vs NT)
NR - NR PHT: 11/62
(18%)
- NT: 0/61 (0%)
Zhang 2000
(PHT vs VAL)
NR NR - PHT: 11/72
(15%)
VAL: 2/80 (3%) -
AED: antiepileptic drug; CBZ: carbamazepine; LEV: levetiracetam; NR: not reported; NT: no treatment; PB: phenobarbital; PHT:
phenytoin; VAL: valproate; ZNS: zonisamide.
aSee Analysis 1.4 for comparative results for deaths and Analysis 1.5 for adverse events.
bResults from these trials reported the number of participants who died or experienced adverse events out of the number of participants
randomised. However, loss to follow-up during the trial was unclear.
cResults from the trials only reported the number of participants who died or experienced adverse events out of the number of
participants who were followed up.
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A P P E N D I C E S
Appendix 1. Cochrane Epilepsy Specialized Register search strategy
#1 MeSH DESCRIPTOR Craniotomy Explode All
#2 craniotom* OR postcraniotom*
#3 supratentorial NEXT surgery
#4 infratentorial NEXT surgery
#5 postoperative NEXT epilep*
#6 post-operative NEXT epilep*
#7 postoperative NEXT seizure*
#8 post-operative NEXT seizure*
#9 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8
#10 INREGISTER AND >04/08/2014:CRSCREATED
#11 #9 AND #10
Appendix 2. CENTRAL via CRSO search strategy
The following was used in the latest update to search CENTRAL via the Cochrane Register of Studies Online (CRSO).
#1 MESH DESCRIPTOR Craniotomy EXPLODE ALL TREES
#2 craniotom* OR postcraniotom*
#3 supratentorial NEXT surgery
#4 infratentorial NEXT surgery
#5 #1 OR #2 OR #3 OR #4
#6 MESH DESCRIPTOR Seizures EXPLODE ALL TREES
#7 seizure*
#8 #6 OR #7
#9 #5 AND #8
#10 postoperative NEXT epilep*
#11 post-operative NEXT epilep*
#12 postoperative NEXT seizure*
#13 post-operative NEXT seizure*
#14 #9 OR #10 OR #11 OR #12 OR #13
#15 * NOT INMEDLINE AND 04/08/2014 TO 26/06/2017:CD
#16 #14 AND #15
The following was used previously to search CENTRAL via the Cochrane Library.
#1 MeSH descriptor Craniotomy explode all trees
#2 (craniotom*)
#3 (postcraniotom*)
#4 (supratentorial NEXT surgery)
#5 (infratentorial NEXT surgery)
#6 (#1 OR #2 OR #3 OR #4 OR #5)
#7 MeSH descriptor Seizures explode all trees
#8 (seizure*)
#9 (#7 OR #8)
#10 (#6 AND #9)
#11 (postoperative NEXT epilep*)
#12 (post-operative NEXT epilep*)
#13 (postoperative NEXT seizure*)
#14 (post-operative NEXT seizure*)
#15 (#10 OR #11 OR #12 OR #13 OR #14)
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Appendix 3. MEDLINE (Ovid) search strategy
This strategy is based on the Cochrane Highly Sensitive Search Strategy for identifying randomised trials (Lefebvre 2011).
1. exp Craniotomy/
2. (craniotom$ or postcraniotom$ or supratentorial surgery or infratentorial surgery).tw.
3. 1 or 2
4. exp Seizures/
5. seizure*.tw.
6. 4 or 5
7. 3 and 6
8. (postoperative epilep$ or postoperative seizure$).tw.
9. 7 or 8
10. (randomized controlled trial or controlled clinical trial or pragmatic clinical trial).pt. or (randomi?ed or placebo or randomly).ab.
11. clinical trials as topic.sh.
12. trial.ti.
13. 10 or 11 or 12
14. exp animals/ not humans.sh.
15. 13 not 14
16. 9 and 15
17. remove duplicates from 16
18. limit 17 to ed=20140804-20170626
19. 17 not (1$ or 2$).ed.
20. 19 and (2014$ or 2015$ or 2016$ or 2017$).dc.
21. 18 or 20
Appendix 4. ClinicalTrials.gov search strategy
(post-craniotomy seizures OR supratentorial craniotomy OR cranial surgery) AND antiepileptic drugs
Appendix 5. ICTRP search strategy
post-craniotomy seizures AND antiepileptic drugs OR supratentorial craniotomy AND antiepileptic drugs OR cranial surgery AND
antiepileptic drugs
WH A T ’ S N E W
Last assessed as up-to-date: 26 June 2017.
Date Event Description
26 June 2017 New search has been performed Searches updated on 26 June 2017; two new studies have
been included (Iuchi 2015; Zhang 2000)
26 June 2017 New citation required but conclusions have not changed Conclusions remain unchanged
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H I S T O R Y
Protocol first published: Issue 3, 2008
Review first published: Issue 2, 2013
Date Event Description
18 June 2015 Amended Minor corrections made
4 August 2014 New search has been performed The searches were updated on 04 August 2014
4 August 2014 New citation required but conclusions have not changed Two new trials have been included (Fuller 2013; Wu
2013); conclusions remain unchanged
C O N T R I B U T I O N S O F A U T H O R S
JenniferWeston and Janette Greenhalgh carried out and completed the original review and the 2014 review update. Janette Greenhalgh,
Yenal Dundar and Sarah Nevitt carried out the 2018 update. Anthony Marson supervised the review. Nikola Vojvodic, Aleksandar
Ristic and Dragoslav Sokic developed the protocol for this review.
D E C L A R A T I O N S O F I N T E R E S T
JG: none known
JW: none known
YD: none known
SN: none known
AGM: a consortium of pharmaceutical companies (GSK, EISAI, UCB Pharma) funded the National Audit of Seizure Management in
Hospitals (NASH) through grants paid to the University of Liverpool. Professor Tony Marson is part funded by National Institute for
Health Research Collaboration for Leadership in Applied Health Research and Care North West Coast (NIHR CLAHRC NWC).
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
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External sources
• National Institute for Health Research, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We were unable to make all the intended comparisons specified in the protocol due to lack of data.
In the 2018 update, where data for each trial are entered into Data and analyses tables to allow for a visual comparisons of results across
trials, we have presented results for all dichotomous outcomes as risk ratios and 95% confidence intervals.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anticonvulsants [adverse effects; ∗therapeutic use]; Carbamazepine [therapeutic use]; Craniotomy [∗adverse effects]; Isoxazoles [thera-
peutic use]; Phenobarbital [therapeutic use]; Phenytoin [therapeutic use]; Randomized Controlled Trials as Topic; Seizures [etiology;
mortality; ∗prevention & control]; Valproic Acid [therapeutic use]
MeSH check words
Humans
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